Skip to main content

Advertisement

SpringerLink
Log in

Systemic therapies and cognitive impairment for breast cancer: an overview of the current literature

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Both endocrine and chemotherapy can be utilized for breast cancer patients’ management, in multiple setting (i.e., primary systemic therapy, adjuvant, metastatic treatment). Health-related quality of life in breast cancer survivors can be significantly influenced by cognitive impairment, which has been related in several previously reported experiences to systemic therapies administration. However, although the growing body of literature, the impact of both chemo- and endocrine therapy on cognitive function is currently unclear, due to many confounding factors (i.e., multiple therapies, duration of therapy, comorbidity, age). The aim of the present review is to present an overview of the current literature concerning the possible influence of endocrine and systemic therapy on breast cancer patients’ cognitive impairment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. DeSantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66:31–42.

    Article  PubMed  Google Scholar 

  2. Harbeck N, Gnant M. Breast cancer. Lancet. 2016 Nov 16. pii: S0140-6736(16)31891-31898.

  3. Munhoz RR, Pereira AAL, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: a systematic review and meta-analysis. JAMA Oncology. 2016;2:65–73.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Colleoni M, Giobbie-Hurder A. Benefits and adverse effects of endocrine therapy. Ann Oncol. 2010;21(Suppl 7):vii107-111.

    Google Scholar 

  5. Lee PE, Tierney MC, Wu W, et al. Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies. Breast Cancer Res Treat. 2016;158:407–20.

    Article  CAS  PubMed  Google Scholar 

  6. National Comprehensive Cancer Network. Bone Cancer (Version 2-2.2017). 2017 http://www.nccn.org/professionals/physician_gls/pdf/bone.pdf. Accessed 25 Feb 2017.

  7. Janelsins MC, Kohli S, Mohile SG, et al. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol. 2011;38:431–8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Shilling V, Jenkins V, Fallowfield L, et al. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol. 2003;86:405–12.

    Article  CAS  PubMed  Google Scholar 

  9. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology. 2006;15:422–30.

    Article  PubMed  Google Scholar 

  10. Palmer JL, Trotter T, Joy AA, Carlson LE. Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv. 2008;2:275–82.

    Article  PubMed  Google Scholar 

  11. Eberling JL, Wu C, Tong-Turnbeaugh R, et al. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage. 2004;21:364–71.

    Article  PubMed  Google Scholar 

  12. Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010;28:1294–300.

    Article  CAS  PubMed  Google Scholar 

  13. Phillips KA, Ribi K, Sun Z, et al. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1–98 randomized trial. Breast. 2010;19:388–95.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Collins B, Mackenzie J, Stewart A, et al. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psycho-Oncology. 2009;18:811–21.

    Article  PubMed  Google Scholar 

  15. Chen X, Li J, Chen J, et al. Decision-making impairments in breast cancer patients treated with tamoxifen. Horm Behav. 2014;66:449–56.

    Article  CAS  PubMed  Google Scholar 

  16. Ganz PA, Petersen L, Bower JE, et al. Impact of adjuvant endocrine therapy on quality of life and symptoms: observational data over 12 months from the mind-body study. J Clin Oncol. 2016;34:816–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Phillips KA, Regan MM, Ribi K, et al. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer. 2016;114:956–64.

    Article  CAS  PubMed  Google Scholar 

  18. Hedayati E, Alinaghizadeh H, Schedin A, et al. Effects of adjuvant treatment on cognitive function in women with early breast cancer. Eur J Oncol Nurs. 2012;16:315–22.

    Article  PubMed  Google Scholar 

  19. Debess J, Riis JO, Engebjerg MC, et al. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat. 2010;121:91–100.

    Article  CAS  PubMed  Google Scholar 

  20. Hermelink K, Henschel V, Untch M, et al. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer. 2008;113:2431–9.

    Article  PubMed  Google Scholar 

  21. Le Rhun E, Delbeuck X, Lefeuvre-Plesse C, Kramar A, et al. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy. Breast Cancer Res Treat. 2015;152:569–80.

    Article  PubMed  Google Scholar 

  22. Hurria A, Patel SK, Mortimer J, et al. The effect of aromatase inhibition on the cognitive function of older patients with breast cancer. Clin Breast Cancer. 2014;14:132–40.

    Article  CAS  PubMed  Google Scholar 

  23. Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292–9.

    Article  CAS  PubMed  Google Scholar 

  24. Hurria A, Rosen C, Hudis C, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006;54:925–31.

    Article  PubMed  Google Scholar 

  25. Hermelink K, Untch M, Lux MP, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 2007;109:1905–13.

    Article  CAS  PubMed  Google Scholar 

  26. Jansen CE, Cooper BA, Dodd MJ, et al. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer. 2011;19:1647–56.

    Article  PubMed  Google Scholar 

  27. Marinac CR, Godbole S, Kerr J, et al. Objectively measured physical activity and cognitive functioning in breast cancer survivors. J Cancer Surviv. 2015;9:230–8.

    Article  PubMed  Google Scholar 

  28. Yamada TH, Denburg NL, Beglinger LJ, Schultz SK. Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci. 2010;22:48–54.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485–93.

    Article  CAS  PubMed  Google Scholar 

  30. Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D. The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational longitudinal study. Breast. 2005;14:142–50.

    Article  CAS  PubMed  Google Scholar 

  31. Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, Ryan CM. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006;15:422–30.

    Article  PubMed  Google Scholar 

  32. Stewart A, Collins B, Mackenzie J, et al. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology. 2008;17:122–30.

    Article  PubMed  Google Scholar 

  33. Vearncombe KJ, Rolfe M, Wright M, et al. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc. 2009;15:951–62.

    Article  PubMed  Google Scholar 

  34. Jim HS, Donovan KA, Small BJ, et al. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer. 2009;115:1776–83.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Goldberg D, Williams P. A user’s guide to the General Health Questionnaire. Windsor: NFER-Nelson; 1988.

    Google Scholar 

  36. Koppelmans V, Breteler MM, Boogerd W, et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30:1080–6.

    Article  PubMed  Google Scholar 

  37. Nguyen CM, Yamada TH, Beglinger LJ, et al. Cognitive features 10 or more years after successful breast cancer survival: comparisons across types of cancer interventions. Psychooncology. 2013;22:862–8.

    Article  PubMed  Google Scholar 

  38. Donovan KA, Small BJ, Andrykowski MA, et al. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005;104:2499–507.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94:828–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:210–8.

    Article  PubMed  Google Scholar 

  41. Scherwath A, Mehnert A, Schleimer B, et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol. 2006;17:415–23.

    Article  CAS  PubMed  Google Scholar 

  42. Falleti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cognit. 2005;59:60–70.

    Article  Google Scholar 

  43. Stewart A, Bielajew C, Collins B, et al. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.

    Article  PubMed  Google Scholar 

  44. Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30:3578–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Van Dyk K, Ganz PA. Doctor, now that my chemotherapy treatment is over, when will my “chemofog” lift? J Clin Oncol. 2016 Dec 28:JCO2016707497 (Epub ahead of print).

Download references

Author information

Author notes

  1. Icro Meattini and Isacco Desideri have equally contributed.

Authors and Affiliations

  1. Azienda Ospedaliero Universitaria Careggi – University of Florence, Largo G.A. Brambilla 3, 50134, Florence, Italy

    Icro Meattini, Isacco Desideri, Giulio Francolini, Agnese Vannini, Marco Perna, Pietro Garlatti, Roberta Grassi & Lorenzo Livi

Authors
  1. Icro Meattini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isacco Desideri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giulio Francolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Agnese Vannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marco Perna
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pietro Garlatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Roberta Grassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lorenzo Livi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Icro Meattini.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meattini, I., Desideri, I., Francolini, G. et al. Systemic therapies and cognitive impairment for breast cancer: an overview of the current literature. Med Oncol 34, 74 (2017). https://doi.org/10.1007/s12032-017-0935-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-017-0935-0

Keywords

Search

Navigation